Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

(2012) Edward B. Garon et al.   Clinical Lung Cancer

Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial

(2012) Rodryg Ramlau et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib and the treatment palette for soft-tissue sarcoma

(2012) Vivien HC Bramwell   LANCET

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity

(2011) D. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cardiovascular toxicity of anti-angiogenic drugs

(2011) Gaetan des Guetz et al.   Targeted Oncology

Ramucirumab (IMC-1121B): a novel attack on angiogenesis

(2010) Jennifer L Spratlin et al.   Future Oncology

Bevacizumab toxicities and their management in ovarian cancer

(2010) Leslie M. Randall et al.   GYNECOLOGIC ONCOLOGY

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Taming Glioblastoma by Targeting Angiogenesis: 3 Years Later

(2010) Eric T. Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

(2010) Yanlan Yu et al.   PLoS One

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy

(2009) R. Cao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands

(2009) Y. Cao   Science Signaling

Hypertension and proteinuria: a class-effect of antiangiogenic therapies

(2008) Vincent Launay-Vacher et al.   ANTI-CANCER DRUGS

Les antiangiogéniques en oncologie digestive

(2008) A. Lièvre et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

(2008) J. Tol et al.   INVESTIGATIONAL NEW DRUGS

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE

Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome

(2008) Y. Xue et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA